Clinical Trials Browser

Phase 2/3 × Recruiting × disitamab vedotin × Clear all

NCT06221748 2024-04-03

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Phase 2/3 Recruiting

Gastrointestinal

Stomach Neoplasms